EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte Studie

Comparative Pharmacokinetics of Two Extended‐Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment

Biao Sun, Li Zhao, Fangliang Gan, Qiong Zhan

Clinical Pharmacology in Drug Development · 2026-06 · 15 (6)

DOI: 10.1002/cpdd.70073 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 29.05.2026. Verfasst von Biao Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Zhejiang Anglikang Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study is to evaluate the pharmacokinetic characteristics, bioequivalence, and safety of two brands of upadacitinib (UPA) extended‐release tablets (15 mg) in healthy Chinese subjects under fasting and postprandial conditions. The plasma concentration of UPA was determined by ultra‐high‐performance liquid chromatography‐tandem mass spectrometry, and pharmacokinetic parameters were calculated using a non‐compartmental model (NCA module) with Phoenix WinNonlin 8.2 (Certara, USA) software, followed by bioequivalence evaluation. The results demonstrate that the 90% confidence intervals for the geometric least‐squares mean ratios of C max , AUC 0–t , and AUC 0–∞ between the test and reference formulations fall within the range of 0.80−1.25, indicating that both formulations are bioequivalent in terms of absorption rate and extent under fasting and postprandial conditions. No serious adverse events occurred, and observed drug‐related adverse events were mild under both conditions, indicating comparable safety of the two formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingHumansTherapeutic EquivalencyTabletsDelayed-Action PreparationsAdultMaleArea Under CurveYoung AdultTandem Mass SpectrometryCross-Over StudiesChromatography, High Pressure LiquidPostprandial PeriodFastingModels, BiologicalHealthy VolunteersFemaleAdministration, Oral

Stichwörter der Autor:innen

UPLC‐MS/MSbioequivalencepharmacokineticsafetyupadacitinib extended‐release tablets

Substanzen

TabletsDelayed-Action PreparationsupadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Pharmacy, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China.
  • Department of Gynecology, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China.
  • Phase I Clinical Trial Unit, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China.

Förderung

  • Zhejiang Anglikang Pharmaceutical Co., Ltd

Zitieren

APA

Sun, B., Zhao, L., Gan, F., & Zhan, Q. (2026). Comparative Pharmacokinetics of Two Extended‐Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment. Clinical Pharmacology in Drug Development, 15(6). https://doi.org/10.1002/cpdd.70073

Vancouver

Sun B, Zhao L, Gan F, Zhan Q. Comparative Pharmacokinetics of Two Extended‐Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment. Clinical Pharmacology in Drug Development. 2026;15(6). doi:10.1002/cpdd.70073

BibTeX
@article{Sun2026,
  author = {Sun, Biao and Zhao, Li and Gan, Fangliang and Zhan, Qiong},
  title = {Comparative Pharmacokinetics of Two Extended‐Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cpdd.70073}
}
Kostenlos starten →